1-6 of 6
Jing Gong
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard Leblanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Facon, Cesar Rodriguez, Ralph Wäsch, Meletios A. Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab
Journal: Blood
Blood (2024) 144 (Supplement 1): 1025.
https://doi.org/10.1182/blood-2024-198408
Published: 2024
Journal Articles

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Paul G. Richardson, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, Robert Z. Orlowski, Kihyun Kim, María-Victoria Mateos, Charlotte Pawlyn, Karthik Ramasamy, Joaquín Martinez-Lopez, Alessia Spirli, Ignacio Casas-Avilés, Jing Gong, Michael Amatangelo, Jessica Katz, Paulo Maciag, Teresa Peluso, Nizar J. Bahlis
Journal: Blood
Blood (2022) 140 (Supplement 1): 1366–1368.
https://doi.org/10.1182/blood-2022-157945
Published: 2022
Journal Articles

Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)

Courtney D. DiNardo, Hartmut Dohner, Amer M. Zeidan, Andre C. Schuh, Paresh Vyas, Eytan M. Stein, Andrew H. Wei, Stephane de Botton, Clara Chen, Jennifer Lord-Bessen, Patricia Martin-Regueira, Frederik Lersch, Jing Gong, Shien Guo, Ling Shi, Pau Montesinos
Journal: Blood
Blood (2021) 138 (Supplement 1): 1244.
https://doi.org/10.1182/blood-2021-147601
Published: 2021
Journal Articles

OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

Farhad Ravandi, Hetty E. Carraway, Lilia Taningco, Kimberley Dilley, Eric Laille, Jing Gong, Daniel Lopes de Menezes, Andrew H. Wei
Journal: Blood
Blood (2021) 138 (Supplement 1): 2314.
https://doi.org/10.1182/blood-2021-147293
Published: 2021
Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 643.
https://doi.org/10.1182/blood-2019-130362
Published: 2019
Journal Articles

Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Courtney D. DiNardo, MDMSc, Anthony S. Stein, MD, Amir T. Fathi, MD MD BS, Pau Montesinos, MD PhD, Olatoyosi Odenike, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Daniel O. Koralek, PhD, Jason Van Oostendorp, M.Sc., Jing Gong, PhD, Ira Gupta, MD, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 639.
https://doi.org/10.1182/blood.V130.Suppl_1.639.639
Published: 2017